DBV Technologies reported $-18020000 in Operating Profit for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
DBV Technologies DBVT:US USD -18020000 5.8M
Acadia Pharmaceuticals ACAD:US USD -30866000 2.78M
Alnylam Pharmaceuticals ALNY:US USD -334626000 142.94M
Amarin AMRN:US USD -5144000 57.69M
Biocryst Pharmaceuticals BCRX:US USD -17445000 17.28M
Biomarin Pharmaceutical BMRN:US USD -2417000 41.57M
Esperion Therapeutics ESPR:US USD -41623000 10.75M
Galectin Therapeutics GALT:US USD -8122000 1.54M
Halozyme Therapeutics HALO:US USD 80.58M 46.52M
Insmed INSM:US USD -127697000 39.38M
Intercept Pharmaceuticals ICPT:US USD -101903000 88.54M
IONIS PHARMACEUT IONS:US USD -59154000 26.36M
Neurocrine Biosciences NBIX:US USD 87.8M 103.1M
Ptc Therapeutics PTCT:US USD -68187000 24.17M
Sarepta Therapeutics SRPT:US USD -256796000 45.66M
Ultragenyx Pharmaceutical RARE:US USD -225066000 83.47M
United Therapeutics UTHR:US USD 314.3M 112.5M
YTE INCY:US USD 138.38M 116.06M